[go: up one dir, main page]

CO2018013029A2 - Uso de indazoles sustituidos para el tratamiento y la prevención de enfermedades en animales - Google Patents

Uso de indazoles sustituidos para el tratamiento y la prevención de enfermedades en animales

Info

Publication number
CO2018013029A2
CO2018013029A2 CONC2018/0013029A CO2018013029A CO2018013029A2 CO 2018013029 A2 CO2018013029 A2 CO 2018013029A2 CO 2018013029 A CO2018013029 A CO 2018013029A CO 2018013029 A2 CO2018013029 A2 CO 2018013029A2
Authority
CO
Colombia
Prior art keywords
animals
treatment
diseases
prevention
substituted indazoles
Prior art date
Application number
CONC2018/0013029A
Other languages
English (en)
Inventor
Ulf Bömer
Reinhard Nubbemeyer
Ulrich Bothe
Gerald Beddies
Adrian Foster
Nicole Schmidt
Maria De Lourdes Mottier
Original Assignee
Bayer Pharma AG
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Animal Health Gmbh filed Critical Bayer Pharma AG
Publication of CO2018013029A2 publication Critical patent/CO2018013029A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere al uso de indazoles sustituidos en el tratamiento y/o profilaxis de enfermedades alérgicas y/o inflamatorias en animales, especialmente para el tratamiento y/o profilaxis de la dermatitis atópica, Dermatitis Alérgica por pulgas, enfermedad intestinal inflamatoria, osteoartritis y dolor inflamatorio, enfermedad de las vías respiratorias recurrente no infecciosa, hipersensibilidad a los insectos, asma, enfermedad respiratoria, mastitis y endometritis en animales.
CONC2018/0013029A 2016-06-01 2018-11-30 Uso de indazoles sustituidos para el tratamiento y la prevención de enfermedades en animales CO2018013029A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16172544 2016-06-01
PCT/EP2017/062876 WO2017207481A1 (en) 2016-06-01 2017-05-29 Substituted indazoles ueful for treatment and prevention of allergic and/or inflammatory diseases in animals

Publications (1)

Publication Number Publication Date
CO2018013029A2 true CO2018013029A2 (es) 2018-12-28

Family

ID=56097024

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0013029A CO2018013029A2 (es) 2016-06-01 2018-11-30 Uso de indazoles sustituidos para el tratamiento y la prevención de enfermedades en animales

Country Status (25)

Country Link
US (2) US20200216413A1 (es)
EP (1) EP3464266B1 (es)
JP (1) JP7004677B2 (es)
KR (1) KR102547834B1 (es)
CN (3) CN120531733A (es)
AU (1) AU2017272505B9 (es)
BR (1) BR112018074927A2 (es)
CA (1) CA3025847A1 (es)
CL (1) CL2018003432A1 (es)
CO (1) CO2018013029A2 (es)
DK (1) DK3464266T3 (es)
DO (1) DOP2018000262A (es)
ES (1) ES2898771T3 (es)
IL (1) IL263132B (es)
MX (1) MX394560B (es)
MY (1) MY199070A (es)
PH (1) PH12018502530A1 (es)
PL (1) PL3464266T3 (es)
PT (1) PT3464266T (es)
RU (1) RU2743170C2 (es)
SG (1) SG11201809470RA (es)
SI (1) SI3464266T1 (es)
TW (1) TWI781935B (es)
UA (1) UA124237C2 (es)
WO (1) WO2017207481A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
JP6947743B2 (ja) 2016-03-03 2021-10-13 バイエル・ファルマ・アクティエンゲゼルシャフト 新規な２−置換インダゾール、その製造方法、それを含有する医薬製剤、および薬物を製造するためのその使用
EP3448848B1 (en) 2016-04-29 2023-09-27 Bayer Pharma Aktiengesellschaft Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
PT3448849T (pt) 2016-04-29 2020-06-30 Bayer Pharma AG Síntese de indazóis
TN2018000409A1 (en) 2016-06-01 2020-06-15 Bayer Pharma AG Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
ES2898771T3 (es) 2016-06-01 2022-03-08 Bayer Animal Health Gmbh Indazoles sustituidos útiles para el tratamiento y la prevención de enfermedades alérgicas y/o inflamatorias en animales
AU2018350683A1 (en) 2017-10-19 2020-04-02 Bayer Animal Health Gmbh Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
PH12021552939A1 (en) 2019-05-23 2022-07-25 The Univ Of Montana Vaccine adjuvants based on tlr receptor ligands
WO2021057785A1 (zh) * 2019-09-24 2021-04-01 上海美悦生物科技发展有限公司 一种irak抑制剂及其制备方法和用途
EP3800188A1 (en) 2019-10-02 2021-04-07 Bayer AG Substituted pyrazolopyrimidines as irak4 inhibitors
JP7429032B2 (ja) * 2019-12-24 2024-02-07 学校法人順天堂 間質性肺炎モデル非ヒト動物の作製方法
CN113521079A (zh) * 2020-04-20 2021-10-22 上海领泰生物医药科技有限公司 Irak4抑制剂在治疗ali/ards中的应用
CN115300627B (zh) * 2021-05-08 2024-01-26 中南大学湘雅医院 钠-葡萄糖共转运蛋白2抑制剂的应用、一种药物组合物及其应用
CN113402499B (zh) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途
KR20250004525A (ko) * 2023-06-29 2025-01-08 동화약품주식회사 신규한 카르복사마이드 유도체 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200003765T2 (tr) 1998-07-01 2001-05-21 The Procter & Gamble Company Zıt akımlı titreşimli darbe gazı kullanılarak lifli tabakadan su ayırmak için işlem
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
RU2005105683A (ru) * 2002-07-31 2006-01-20 Шеринг Акциенгезельшафт (De) Обладающие ингибирующим действием на vegfr-2 и vegfr-3 антраниламидопиридины
US20070179143A1 (en) 2003-06-25 2007-08-02 Je Il Pharmaceutical Co., Ltd. Tricyclic derivatives or pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them
WO2005026129A1 (en) 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
WO2005082866A2 (en) 2004-02-20 2005-09-09 Pfizer Limited Substituted 1, 2, 4- triazole derivatives as oxytocin antagonists
CA2591332A1 (en) 2004-12-08 2006-06-15 Warner-Lambert Company Llc Methylene inhibitors of matrix metalloproteinase
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
GT200600411A (es) 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
SI3184526T1 (sl) 2005-12-13 2019-03-29 Incyte Holdings Corporation Derivati pirolo(2,3-D)pirimidina kot inhibitorji Janus kinaze
US7745477B2 (en) 2006-02-07 2010-06-29 Hoffman-La Roche Inc. Heteroaryl and benzyl amide compounds
WO2007091107A1 (en) 2006-02-10 2007-08-16 Summit Corporation Plc Treatment of duchenne muscular dystrophy
CN101511840A (zh) 2006-04-26 2009-08-19 吉宁特有限公司 磷酸肌醇3-激酶抑制剂化合物及其使用方法
WO2008001883A1 (en) 2006-06-29 2008-01-03 Nissan Chemical Industries, Ltd. α-AMINO ACID DERIVATIVE AND PHARMACEUTICAL COMPRISING THE SAME AS ACTIVE INGREDIENT
CA2663100A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
WO2009117421A2 (en) 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
US8524751B2 (en) 2009-03-09 2013-09-03 GlaxoSmithKline Intellecutual Property Development 4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
WO2011153588A1 (en) 2010-06-10 2011-12-15 Biota Scientific Management Pty Ltd Viral polymerase inhibitors
US20140113898A1 (en) 2010-11-08 2014-04-24 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
US8507499B2 (en) 2010-12-06 2013-08-13 Confluence Life Sciences, Inc. Substituted indole/indazole-pyrimidinyl compounds
CA2822166C (en) 2010-12-20 2019-10-29 Merck Serono S.A. Indazolyl triazole derivatives as irak inhibitors
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US8748432B2 (en) 2011-02-10 2014-06-10 Syngenta Participations Ag Microbiocidal pyrazole derivatives
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
CA2827311A1 (en) 2011-02-18 2012-08-23 Vertex Pharmaceuticals Incorporated Chroman-spirocyclic piperidine amides as modulators of ion channels
US8575336B2 (en) * 2011-07-27 2013-11-05 Pfizer Limited Indazoles
WO2013042137A1 (en) * 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
WO2013106254A1 (en) 2012-01-11 2013-07-18 Dow Agrosciences Llc Pesticidal compositions and processes related thereto
CA2860250C (en) 2012-02-21 2020-11-10 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
CN104507950B (zh) 2012-05-21 2017-03-22 拜耳医药股份有限公司 噻吩并嘧啶
WO2015017336A1 (en) * 2013-07-29 2015-02-05 OmniGen Research, L.L.C. Combination and method for administration to an animal
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
JP2017505337A (ja) 2014-01-10 2017-02-16 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ４阻害剤としてのインダゾール化合物
MX2016017147A (es) 2014-06-20 2017-06-07 Aurigene Discovery Tech Ltd Compuestos de indazole substituidos como inhibidores de irak4.
CN104093061B (zh) 2014-07-18 2020-06-02 北京智谷睿拓技术服务有限公司 内容分享方法和装置
JO3705B1 (ar) * 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
TW201701879A (zh) * 2015-04-30 2017-01-16 拜耳製藥公司 Ｉｒａｋ４抑制劑組合
PT3448849T (pt) * 2016-04-29 2020-06-30 Bayer Pharma AG Síntese de indazóis
EP3448848B1 (en) * 2016-04-29 2023-09-27 Bayer Pharma Aktiengesellschaft Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
ES2898771T3 (es) 2016-06-01 2022-03-08 Bayer Animal Health Gmbh Indazoles sustituidos útiles para el tratamiento y la prevención de enfermedades alérgicas y/o inflamatorias en animales
TN2018000409A1 (en) 2016-06-01 2020-06-15 Bayer Pharma AG Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases

Also Published As

Publication number Publication date
AU2017272505B9 (en) 2021-10-28
CN120531733A (zh) 2025-08-26
UA124237C2 (uk) 2021-08-11
DOP2018000262A (es) 2019-02-28
CL2018003432A1 (es) 2019-03-22
PL3464266T3 (pl) 2022-01-24
AU2017272505A8 (en) 2018-11-29
KR20190015252A (ko) 2019-02-13
CN119367364A (zh) 2025-01-28
WO2017207481A8 (en) 2018-11-22
SI3464266T1 (sl) 2021-12-31
US20200216413A1 (en) 2020-07-09
TWI781935B (zh) 2022-11-01
PT3464266T (pt) 2021-11-23
KR102547834B1 (ko) 2023-06-26
WO2017207481A1 (en) 2017-12-07
JP7004677B2 (ja) 2022-01-21
RU2018145860A3 (es) 2020-07-09
DK3464266T3 (da) 2021-11-22
RU2743170C2 (ru) 2021-02-15
BR112018074927A2 (pt) 2019-03-12
US20220204474A1 (en) 2022-06-30
SG11201809470RA (en) 2018-11-29
CA3025847A1 (en) 2017-12-07
MY199070A (en) 2023-10-12
TW201808933A (zh) 2018-03-16
EP3464266B1 (en) 2021-10-20
IL263132B (en) 2022-04-01
AU2017272505A1 (en) 2018-11-15
NZ747414A (en) 2025-06-27
PH12018502530A1 (en) 2019-10-21
JP2019520348A (ja) 2019-07-18
CN109219603A (zh) 2019-01-15
IL263132A (en) 2018-12-31
MX394560B (es) 2025-03-24
ES2898771T3 (es) 2022-03-08
EP3464266A1 (en) 2019-04-10
MX2018014899A (es) 2019-04-24
RU2018145860A (ru) 2020-07-09
US12459916B2 (en) 2025-11-04
AU2017272505B2 (en) 2021-10-07
CN109219603B (zh) 2025-06-27

Similar Documents

Publication Publication Date Title
CO2018013029A2 (es) Uso de indazoles sustituidos para el tratamiento y la prevención de enfermedades en animales
IL280710A (en) Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
CL2018000039A1 (es) Derivados de oxopiridina sustituidos
HUE051114T2 (hu) Mikrobiális közösségek alkalmazása emberek és állatok egészségéhez
ES2820879R1 (es) Composiciones para la liberación controlada de ingredientes activos y métodos de preparación de las mismas
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
IL268850A (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
IL262702B (en) Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
HUE066811T2 (hu) Izoxazolin kompozíciók és azok felhasználása parazitafertõzések megelõzésében és kezelésében állatokban
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
PT3723739T (pt) Formulações de parasiticida isoxazolina e sua utilização para o tratamento de blefarite
AR106644A1 (es) Composiciones nutricionales sinergísticas y usos de las mismas
IL268720A (en) Formulations of cannabinoids for the treatment of dermatitis and inflammatory skin diseases
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
CL2018000433A1 (es) Procedimientos para mejorar la salud de peces de cultivo.
ES2699722R1 (es) Composicion para tratar enfermedades de las neuronas motoras y uso de la misma
UY37671A (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
UY37622A (es) Derivados de pirazol como inhibidores de bromodominio de la familia bet y su uso en aplicaciones terapéuticas
CO2017000745A2 (es) Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrófila
EA201890188A1 (ru) Новый бициклический липолантипептид, его получение и применение в качестве противомикробного средства
CL2018002368A1 (es) Formulaciones de oritavancina
BR112017008734A2 (pt) acelerador de produção de proteína tau e agente preventivo ou terapêutico e composição alimentícia preventiva ou terapêutica para doenças causadas por deficiência de proteína tau